DDW In Focus e-report on the future of antibody-based drugs


Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here. 

This report will:  

  • Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future 
  • Explore what’s next for antibody-based drugs and where the opportunity is coming from 
  • Include an interview Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery  
  • Share significant future trends for the therapeutic antibody market 

Key insights:  

  • The global mAb market size was valued at $185.50 billion in 2021 
  • Biopharmas originating in China will likely have greater influence on the industry by 2028 
  • The lessons learned from mAb development for SARS-CoV-2 will likely provide an important platform for the scientific community 
  • With over 10 biosimilars approved, Argentina and Brazil have the most biosimilar monoclonal antibodies approved in Latin America
  • Of the total number of antibody drugs approved worldwide, 93% were approved first by four drug regulatory agencies: the FDA, EMA, PMDA and NMPA 

Download this report now to learn more.  

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free